BioMarin a Buy with a $28 Target

BioMarin Pharmaceutical Inc. (BMRN - Analyst Report) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder
mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI.

Recently, the company received both FDA and EC approval for its third product, Kuvan, for the treatment of PKU. Strong product sales will drive the company to profitability in 2008 and beyond.

The company's clinical pipeline, too, remains impressive. As such, we maintain our Buy rating on the stock with a price target of $28.

Read the full analyst report on BMRN